KPTI - Karyopharm Therapeutics Inc
IEX Last Trade
0.7593
-0.012 -1.515%
Share volume: 481,269
Last Updated: Fri 30 Aug 2024 09:53:18 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.77
-0.01
-1.49%
Fundamental analysis
41%
Profitability
50%
Dept financing
25%
Liquidity
67%
Performance
30%
Performance
5 Days
-8.79%
1 Month
-28.28%
3 Months
-19.83%
6 Months
-42.84%
1 Year
-44.51%
2 Year
-84.92%
Key data
Stock price
$0.76
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.62 - $1.95
52 WEEK CHANGE
-$0.44
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Michael Kauffman
Region: US
Website: https://karyopharm.com/
Employees: 506
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://karyopharm.com/
Employees: 506
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com
Recent news